Thomas R. Staab II is President & CFO +1 at BIOCRYST PHARMACEUTICALS INC (BCRX). They have made 3 open-market trades across 2 companies since 2018, most recently 2026-09-11.
CIK 0001230708
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $11K since 2026, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| BCRX | 137,383 | $1.1M |
| LNSR | 174,609 | $1.0M |
| TENX | 15,675 | $21K |
| Total | $2.1M |
Shares reported on the most recent Form 4, priced at the 2026-09-15 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.